ArticleVirology2022

Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants.

Rui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.